Generic drug company Teva Pharmaceutical Industries Ltd. said Monday regulators approved Azilect, the company's treatment for Parkinson's disease, for sale and marketing in Canada.

Health Canada gave the green light to the drug for initial monotherapy in early Parkinson's disease and as adjunct therapy to levodopa in moderate to advanced disease, the company said. The company expects to begin selling the drug in Canada in September.

The company said the approval was based on three studies on more than 1,500 patients.

NEWS ARCHIVES

2008

• September
• August
• July
• June
• May
• April
• March

2007

• April
• March
• February
• January

2006

• December
• November
• October
• September
• August
• July
• June
• May
• April
• March
• February
• January

2005

• December
• November
• October
• August
• June
• April
• March
• February

2004

• December

NEWSLETTER SIGNUP